A Rho-kinase inhibitor, fasudil, attenuates progressive glomerulosclerosis induced by daunorubicin in rats
- PMID: 20037814
- DOI: 10.1007/s11596-009-0609-z
A Rho-kinase inhibitor, fasudil, attenuates progressive glomerulosclerosis induced by daunorubicin in rats
Abstract
Accumulating evidence suggests that the small G protein Rho and its downstream effector Rho kinase may play important roles in kidney biology. The present study examined the effects of a Rho-kinase inhibitor, fasudil, on daunorubicin-induced progressive glomerulosclerosis and explored the underlying mechanism by which fasudil ameliorates glomerulosclerosis. Thirty-six male SD rats were randomly allocated into sham-operation group (sham group, n=12), unilateral nephrectomy (UNX)+daunorubicin (DRB) group (model group, n=12), UNX+DRB+Fasudil group (treatment group, n=12). Two to four weeks after the establishment of the animal model, 6 rats in each group were taken randomly for the detection of 24-h urine protein excretion. Kidney sections were examined by HE and PAS staining, immunohistochemistry and transmission electric microscopy (TEM). The expression of Rho-kinase mRNA and P27 mRNA in kidney were detected by RT-PCR. It was found that the 24-h urine protein excretion in model group was increased significantly as compared with sham group (P<0.01). But this increase was significantly suppressed by fasudil (P<0.05). At 4 week, the foot process effacement in podocytes, mesangial proliferation and ECM accumulation were observed in model group, presenting as focal segmental glomerulosclerosis. But in the treatment group, the fasudil alleviated glomerular injury, with proliferating cell nuclear antigen (PCNA)-positive cell infiltration ameliorated and the expression of P27 increased. The expression of Rho-kinase mRNA was significantly enhanced in model group and was suppressed in treatment group. Moreover, fasudil up-regulated the mRNA expression of P27. Our study demonstrated that the glomerulosclerosis was substantially ameliorated by inhibiting the expression of Rho-kinase. It is suggested that Rho-kinase pathway is involved in the renal injury and the inhibition of Rho-kinase may constitute a therapeutic strategy for the treatment of renal injury.
Similar articles
-
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.Kidney Int. 2003 Dec;64(6):2009-19. doi: 10.1046/j.1523-1755.2003.00300.x. Kidney Int. 2003. PMID: 14633123
-
Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats.J Hypertens. 2004 Sep;22(9):1787-96. doi: 10.1097/00004872-200409000-00024. J Hypertens. 2004. PMID: 15311108
-
Rho kinase inhibition by fasudil attenuates cyclosporine-induced kidney injury.J Pharmacol Exp Ther. 2011 Jul;338(1):271-9. doi: 10.1124/jpet.111.179457. Epub 2011 Apr 7. J Pharmacol Exp Ther. 2011. PMID: 21474569
-
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.J Pharmacol Sci. 2006 Jan;100(1):29-33. doi: 10.1254/jphs.fmj05003x6. Epub 2006 Jan 6. J Pharmacol Sci. 2006. PMID: 16397371 Review.
-
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.J Pharmacol Sci. 2006 Jan;100(1):22-8. doi: 10.1254/jphs.fmj05003x5. Epub 2006 Jan 6. J Pharmacol Sci. 2006. PMID: 16397372 Review.
Cited by
-
Rho-Associated Kinase Inhibitor Fasudil Protects from Sepsis-Induced Acute Kidney Injury in Rat via Suppressing STAT-3 and NLRP-3 Pathway.Curr Issues Mol Biol. 2025 May 8;47(5):340. doi: 10.3390/cimb47050340. Curr Issues Mol Biol. 2025. PMID: 40699739 Free PMC article.
-
Metabolomics study of fasudil on cisplatin-induced kidney injury.Biosci Rep. 2019 Nov 29;39(11):BSR20192940. doi: 10.1042/BSR20192940. Biosci Rep. 2019. PMID: 31670380 Free PMC article.
-
RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis.Oncotarget. 2018 Jan 12;9(18):14397-14412. doi: 10.18632/oncotarget.24208. eCollection 2018 Mar 6. Oncotarget. 2018. PMID: 29581852 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous